Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVO-CTEPH: Levosimendan in CTEPH After Pulmonary Thromboendarterectomy
NCT07914933Recruiting
- Sponsor
- E. Meshalkin National Medical Research Centre
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of levosimendan in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by E. Meshalkin National Medical Research Centre. Primary endpoint: Mean pulmonary artery pressure at 24 hours. Started Apr 2025; status: recruiting.
02
Drugs
levosimendan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT07914933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914933.